Alumis (NASDAQ:ALMS) Sets New 12-Month High on Insider Buying Activity

Alumis Inc. (NASDAQ:ALMS) reached a new 52-week high during trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $22.39 and last traded at $21.98, with a volume of 1607602 shares traded. The stock had previously closed at $21.09.

Specifically, Director Srinivas Akkaraju purchased 588,235 shares of the company’s stock in a transaction on Friday, January 9th. The shares were bought at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the transaction, the director directly owned 1,853,488 shares in the company, valued at approximately $31,509,296. This represents a 46.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Foresite Labs, Llc purchased 411,764 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In related news, Director James B. Tananbaum acquired 411,764 shares of the stock in a transaction dated Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the director owned 5,702,536 shares in the company, valued at approximately $96,943,112. The trade was a 7.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

ALMS has been the subject of several research analyst reports. UBS Group reiterated an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective (up previously from $20.00) on shares of Alumis in a research report on Friday, January 9th. Leerink Partners increased their target price on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Citigroup restated an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $50.00 price objective on shares of Alumis in a research report on Tuesday, January 6th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju purchased 588,235 shares at $17.00 (~$10.0M), increasing his stake by ~46% — a material insider buy that signals management confidence. Read More.
• Positive Sentiment: Director James B. Tananbaum (and affiliated Foresite entities) bought 411,764 shares at $17.00 (~$7.0M), lifting their holdings materially — institutional/insider demand typically boosts sentiment and liquidity. Read More.
• Positive Sentiment: Major shareholder Foresite Labs/Capital increased its position (411,764 shares at $17), reinforcing institutional support and amplifying the buying pressure. Read More.
• Positive Sentiment: Market headlines cite positive plaque‑psoriasis data for lead candidate Envudeucitinib — the clinical update is a direct fundamental catalyst behind the rapid run‑up in the stock. Read More.
• Positive Sentiment: An analyst price‑target lift was reported (79.14% increase to $36.28), reflecting the same bullish re‑rating driving buy‑side interest. Read More.
• Neutral Sentiment: Several firms have reissued “outperform/buy” ratings and higher targets (MarketBeat/coverage roundup); broader analyst coverage likely magnifies volatility but also improves liquidity. Read More.
• Neutral Sentiment: Institutional ownership changes (historic buys by multiple funds) mean the stock can see larger block trades and volume swings; that can support rallies but also increases headline sensitivity. Read More.
• Negative Sentiment: Fundamental risk remains: Alumis missed most recent quarterly EPS and revenue estimates and is loss‑making — clinical execution or disappointing future readouts could quickly reverse gains. Read More.

Alumis Stock Up 10.1%

The company has a market cap of $2.54 billion, a P/E ratio of -6.01 and a beta of -2.09. The firm has a fifty day moving average price of $10.29 and a 200 day moving average price of $6.34.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. On average, sell-side analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Stonepine Capital Management LLC bought a new position in Alumis in the 2nd quarter valued at $1,049,000. Trium Capital LLP boosted its holdings in Alumis by 17.9% in the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock valued at $12,457,000 after acquiring an additional 474,072 shares during the last quarter. General Atlantic L.P. acquired a new stake in Alumis in the second quarter worth about $3,893,000. Velan Capital Investment Management LP bought a new stake in Alumis during the 2nd quarter worth about $4,863,000. Finally, Los Angeles Capital Management LLC acquired a new position in Alumis during the 2nd quarter valued at about $368,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.